BlueRock Therapeutics Announces First Patient Treated in Pivotal Phase III Parkinson’s Trial
BlueRock Therapeutics, a subsidiary of Bayer, has announced a significant milestone in the development of a new treatment for Parkinson’s disease. The first patient has been treated in their pivotal Phase III clinical trial, known as exPDite-2. This trial will evaluate the safety and effectiveness of bemdaneprocel, an investigational cell therapy. The trial is the first […]
BlueRock’s Phase I Study with Bemdaneprocel in Parkinson’s Disease Patients Achieves Main Goal
BlueRock Therapeutics, in collaboration with Bayer AG, recently announced the successful results of their Phase I clinical trial for bemdaneprocel (BRT-DA01), an innovative cellular therapy derived from stem cells, aimed at treating Parkinson’s disease. The findings were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Key Highlights: Dr. Claire […]